CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy.
Saved in:
| Title: | CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy. |
|---|---|
| Authors: | Vitali A; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Padlo J; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Caramel C; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Andersch L; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany.; German Cancer Consortium (DKTK), Partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Hartmann LM; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin, Germany., Kath J; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin, Germany., Grunewald L; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Schwiebert S; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Winkler A; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Talalai E; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Biereder T; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Wienke J; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands., Launspach M; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany.; German Cancer Consortium (DKTK), Partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin, Germany., Delebinski C; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Kern A; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Astrahantseff K; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Wagner DL; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin, Germany., Willimsky G; German Cancer Consortium (DKTK), Partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Tumor Immunology, Berlin, Germany., Eggert A; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany.; University Hospital Essen, Essen, Germany., Blankenstein T; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Tumor Immunology, Berlin, Germany., Anders K; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany., Künkele A; Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Paediatric Oncology and Haematology, Berlin, Germany.; German Cancer Consortium (DKTK), Partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Sep 18; Vol. 17, pp. 1901504. Date of Electronic Publication: 2026 Sep 18 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1901504 |
